Haemonetics Corp. (HAE) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Masimo Corp.

Envista Holdings Corp.

Lantheus Holdings, Inc.

Natera, Inc.

Inspire Medical Systems, Inc.

Shockwave Medical, Inc.

Bio-Rad Laboratories, Inc.

Haemonetics Corp.

Bausch + Lomb Corp.

QuidelOrtho Corp.

Dentsply Sirona, Inc.

Why is Haemonetics Corp. ?

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 8.96

Poor long term growth as Net Sales has grown by an annual rate of 7.32% and Operating profit at 8.03% over the last 5 years

Flat results in Jun 25

DEBT-EQUITY RATIO (HY) Highest at 105.62 %
INTEREST(Q) At USD 4.07 MM has Grown at inf%
INVENTORY TURNOVER RATIO(HY) Lowest at 1.69 times

With ROCE of 12.30%, it has a attractive valuation with a 2.47 Enterprise value to Capital Employed

The stock is trading at a discount compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 1.33%, its profits have risen by 1.5% ; the PEG ratio of the company is 8.4

Underperformed the market in the last 1 year

The stock has generated a return of 1.33% in the last 1 year, much lower than market (S&P 500) returns of 14.11%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Haemonetics Corp. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Haemonetics Corp.

-0.26%

-0.03

53.55%

S&P 500

20.78%

0.70

20.15%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

8.32%

EBIT Growth (5y)

15.08%

EBIT to Interest (avg)

8.96

Debt to EBITDA (avg)

2.49

Net Debt to Equity (avg)

1.13

Sales to Capital Employed (avg)

0.67

Tax Ratio

20.93%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

10.56%

ROE (avg)

14.77%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.76

EV to EBIT

13.85

EV to EBITDA

9.47

EV to Capital Employed

1.90

EV to Sales

2.56

PEG Ratio

0.52

Dividend Yield

ROCE (Latest)

13.73%

ROE (Latest)

19.13%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD 293.22 MM

RAW MATERIAL COST(Y)

Fallen by 1.52% (YoY

NET SALES(Q)

Highest at USD 346.35 MM

NET PROFIT(Q)

Highest at USD 53.18 MM

-13What is not working for the Company

INTEREST COVERAGE RATIO(Q)

Lowest at 1,157.98

INTEREST(HY)

At USD 14.95 MM has Grown at 34.83%

ROCE(HY)

Lowest at 12.03%

DEBT-EQUITY RATIO (HY)

Highest at 129.25 %

OPERATING PROFIT(Q)

Lowest at USD 79.07 MM

OPERATING PROFIT MARGIN(Q)

Lowest at 22.83 %

PRE-TAX PROFIT(Q)

Lowest at USD 44.92 MM

EPS(Q)

Lowest at USD -0.44

Here's what is working for Haemonetics Corp.

Operating Cash Flow

Highest at USD 293.22 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Sales

Highest at USD 346.35 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Net Profit

Highest at USD 53.18 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

Raw Material Cost

Fallen by 1.52% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Haemonetics Corp.

Interest Coverage Ratio

Lowest at 1,157.98 and Fallen

In each period in the last five periods

MOJO Watch

The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Interest

At USD 14.95 MM has Grown at 34.83%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Operating Profit

Lowest at USD 79.07 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Operating Profit Margin

Lowest at 22.83 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

Lowest at USD 44.92 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Pre-Tax Profit

At USD 44.92 MM has Fallen at -20.89%

over average net sales of the previous four periods of USD 56.78 MM

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

EPS

Lowest at USD -0.44

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (USD)

Debt-Equity Ratio

Highest at 129.25 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio